2027 SPEAKERS
Ana Filipa Alexandre, Senior Director, Pipeline Head for Neuroscience, Teva Pharmaceuticals
Eunice Alvazzi, Global Head, Hematology, Nephrology, Transplant & Neurology, Access & Pricing, Alexion – AstraZeneca Rare Disease
Georges André, President, Institut Français Valeur en Santé
Michael Andreou, Value & Access Lead, Rare Diseases, Biogen, Biogen
Marta Andreykiv, VP, Viatris
Ad Antonisse, Director, Market Access & Corporate Affairs, AstraZeneca
Jorge Arellano, Senior Vice President, Global Head PAVE, Pricing, Access, Value & Evidence, BioMarin
Fabienne Bartoli, Inspector General, French National Authority for Health
Alex Bastian, Vice President, Commercial Strategy, Memo Therapeutics
Stefano Benvenuti, Head of Public Affairs and Market Access, Fondazione Telethon
Tomer Benzaken, Head of Commercial Operations & Trade, Astellas
Rimma Berenstein, Deputy Head, Pharmaceuticals Department, G-BA
Katja Berg, Global Director, Innovative Value and Access Strategy, Global Market Access and Pricing, BBU, AstraZeneca
Ingrid Bettum, Senior Adviser, Unit for HTA Cancer Medicines, Norwegian Medicines Agency
Thomas Bols, Head of Government Affairs and Patient Advocacy, EMEA & APAC, PTC Therapeutics
Pedro Borga, Global Pricing Director, BioMarin Pharmaceutical Inc.
Okke-Jaap Bosgra, Director International Market Access, Natera
Vidya Breeveld, founder & CEO, Transmineo
Thomas Broekhoff, Program Manager Medicines, hollandbio
Henriette Burghoorn, Associate Director, Market Access, Gilead Sciences
Lorenzo Capretto, Head of HTA Strategy and Pricing, Global Rare Disease, Chiesi Farmaceutici SpA
Antonella Cardone, CEO, Cancer Patients Europe
Lamis Chahoud, Head of Access & Pricing Region New Markets, BeOne Medicines
Bruno Cherel, Senior Director, Head of Pricing, Jazz Pharmaceuticals
Jag Chhatwal, Director, Center for Health Technology Assessment, Harvard Medical School
José Luis Sánchez Chorro, Director, Market Access, Public Affairs, Tenders and Supply, ADVANZ PHARMA
Sally Chung, Vice President, Global Value & Access International Operations & Excellence, Ipsen
Graham Cookson, CEO, Office of Health Economics
Marie-Monique de Molliens, Global Market Access Horizon Scanning Senior Director, Sanofi
Rossella Di Bidino, Head of HTA for AI Unit, Graduate School of Health Economics and Management ALTEMS
Jose Diaz, Global Health Systems Economics & Value of Innovation, BMS
Eva Susanne Dietrich, Professor, Departments for Clinical Pharmacy and Regulatory Affairs, University of Bonn
Toon Digneffe, Head Public Affairs & Public Policy, Takeda
Riad Dirani, Vice President, Global Health Economics, Value and Outcomes, Teva Pharmaceuticals
Maurice Driessen, Senior Director, Head of Inline Brands, GHEVO, Teva Pharmaceuticals
Marcus Droege, Executive Vice President, Managing Director, Pharmaconcepts
Marieangela Economopoulou, Head of Access & External Affairs SEE Region, UCB
Maria Eriksson, Medical Assessor, Ph D., TLV
Karen Facey, Chair HTAi Rare Disease Interest Group, University of Edinburgh
Stefaan Fiers, Chapter Head, External Affairs, Roche
Steven Flostrand, Executive Director, Value, Access & Pricing, Incyte Corp.
Katie Gardner, Global Head of Market Access Excellence & Capabilities, Astellas
Ramiro Gilardino, Associate Professor of Public Health, Buenos Aires School of Public Health
Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson Innovative Medicine
Aveline Godard, Head of Global Pricing & Tendering, Ferring
Enric Gomez, Director Strategy, Pricing & Analytics, Merck Group
Brad Groves, Director, NICE Advice, National Institute for Health & Care Excellence (NICE)
Thomas Grub, Director, Global Pricing and Market Access, Medac GmbH
Neil Grubert, Global Market Access Expert, Independent
Marlene Gyldmark, EU HTA lead, BeOne Medicines
Karla Hernandez-Villafuerte, Senior Researcher, Health Economics, WifOR
Patrick Hopkinson, Independent HTA Expert, Independent HTA Expert
Amy Israel, Senior Advisor, Access to Medicines, Union for International Cancer Control
Jayasree Iyer, Chief Executive Officer, Access to Medicine Foundation
Nicolas Jamet, Global Pricing and Market Access Lead, GSK
Sophie Janssens, Sr VP, Global Head of Patient Impact Maximization (GO), UCB
Iroda Jurabekova, Executive Director, Global Market Access, Oncology, Boehringer Ingelheim
Madhu Kabra, Global Director, HEOR, MKGlobal
Laurie Kan, Sr. Director, Global Market Access, CSL
Elizabeth Kinter, Vice President, Head of Global Market Access, Avidity BioSciences
Sven Klijn, Director, HEOR Evidence Acceleration & Innovation, Bristol Myers Squibb
Jolanda Koenders, Head lx, Takeda
Gavin Lewis, Senior Vice President, Head of Value and Access, Novartis
Mira Ludwikowska, Co-Chair of the JSC Subgroup, Agency for Health Technology Assessment and Tariff System
Charles Makin, Head of US Real World Evidence & Epidemiology, Boehringer Ingelheim
Bill Malcolm, Executive Director, Global HEOR EAI, Bristol Myers Squibb
Marco Marchetti, Co-Chair, HTA Coordination Group & Director, Health Technology Assessment Unit, European Commission & National Agency for Regional Care Services, Italy
Silvy Mardiguian, Head of HEOR, Europe & New Markets, BeOne Medicines
Sandra Margunato Debay, Executive Director, Global Value, Access and Pricing, Revolution Medicines
Emanuele Marsili, Global Access Lead, CSL
Klara Marton, International Strategic Business Development Director, Egis Pharmaceuticals Plc
Vanessa Mirsky, Vice President, Life Sciences Data Strategy, RWE/RWD, OneOncology
Alessandro Monaco, General Manager, Oliba Healthcare and Pharma
Santiago Moreno, Global Head HEOR, Menarini
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
Gorden Muduma, Senior Director Market Access -EMEA Region, Orchard Therapeutics
Michael Mueller, Head of Market Access, Western Europe, Sun Pharma
Thomas Müller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Anh Bourcet Nguyen, International Director, Government Affairs and Policy, Rare Diseases, AstraZeneca
Funmi Oluwa, Head of Market Access & External Engagement, UCB Pharma
Siew Ong, Senior Director, Cytokinetics
Gianfranco Parlato, Global Head of Value Access, Pricing & Policy CMVD (CardioMetabolism & Venous Diseases), Servier International
Adam PARNABY, Lead, Global Policy & Access, Bristol Myers Squibb
Peter Pemberton-Ross, Head, HE & HTA Strategy, Biogen
Tomaso Piaggio, Head of International Market Access, Pricing & Policy, Alnylam Pharmaceuticals
Trine Pilgaard, Director, Head of Market Access, Denmark and Iceland, Pfizer
Uffe Ploug, Global Health Economics Director, UCB
Luca Luigi Polastri, Global Value and Access Head, Nephrology Franchise, Kyowa Kirin
Annette Powers, Senior Vice President, Global Access & Value and Public Policy (GAVP), Astellas
Jennifer Quinn, Senior Director, Head of Market Access, Europe and International, Jazz Pharmaceuticals
Marco Rauland, Vice President, Market Access, Strategy, Pricing and Analytics, Merck KGaA
Magdalena Rdzanek, Consultant, AOTMiT
Adriana Robayo, Executive Director, Instituto de Evaluaci�n Tecnol�gica en Salud (IETS)
Sandra Rose, Head of Market Access & Public Affairs, Chiesi
Mihai Rotaru, Director, Market Access, EFPIA
Charlotte Roy, Life Sciences Policy and Influencing Manager, The Muscular Dystrophy U.K.
Stephanie Said, Coordination EU HTA Medicinal Products, G-BA
Noem Sain, EU Market Access Lead, UCB Pharma
Steve Sandor, Vice President, Market Access, Trade and Government Affairs, Paratek Pharmaceuticals , Inc.
Natalia Scherff, Leadership Coach, INSEAD, ICF PCC, Coach Scherff
Ayman Semaan, Head of Market Access & Pricing, Biologix
Hans Severens, Independent HTA Expert, Severens HTA consultancy
Steve Sharp, Scientific Advisor, National Institute for Health and Care Excellence
Barinder Singh, Founder & Director, Pharmacoevidence
Marta Slomka, Vice Director, Agency for Health Technology Assessment and Tariff System
Jiri Smejkal, Access & Value Head PDT, Takeda
Joshua Smeltzer, Head of Pricing & Contracting, Market Access Germany, Ipsen Pharma GmbH
Raphael Sonabend-Friend, Associate Director, National Institute for Health and Care Excellence
Manoj Sood, Commercial Access Director, Independent Market Access Expert
Andrew Spiegel, CEO, Global Colon Cancer Association
Lotte Steuten, Deputy CEO, Office of Health Economics
Valentina Strammiello, Interim Executive Director, European Patients' Forum
Jan Swiderski, Head of Government Affairs & Policy, KYOWA KIRIN International
Neeta Tandon, Vice President, Value & Evidence Scientific Engagement, Johnson & Johnson Innovation
Siguroli Teitsson, Director, GHEOR Economic & Predictive Modeling, Bristol Myers Squibb
Elena Tricca, Vice President, Global Market Access and Pricing, BioPharmaceuticals, AstraZeneca
Stine Trolle, Senior Advisor, Danish Medicines Agency (DKMA)
Sheela Upadhyaya, Life Science Advisor and Founder, Rarely Ordinary
Caroline van der Meijden, Director, iMTA
Goedele Van Haasteren, Staff Member, Federal Office of Public Health, Switzerland
Oliver van Zon, VP Market Access Europe, Crinetics Pharmaceuticals
Yvette Venable, Global Senior Director of Payer Partnerships and Policy, AstraZeneca
Annemiek Verkamman, Managing Director, hollandbio
Anna Vicere, Director, Access Policy & Public Affairs, Vaccines Europe
Rosa Maria Vivanco Hidalgo, Head of Health Technology Assessment, AQuAS Gencat
Reg Waldeck, Vice President, Head Global Market Access, Bayer
Billy West, Equitable Access Lead, Wellcome Trust
Anne Willemsen, Chair JCA Subgroup, Zorginstituut Nederland
Tonya Winders, President, gaapp.org
Keir Woods, Vice President, Global Value Demonstration, Market Access & Pricing (GVAP), Oncology, Merck Group
Get Involved
Sponsorship & Exhibition Sales
Oliver Hersey-Swan
oliver.hersey-swan@terrapinn.com
Speaking Opportunities
Isla Sutherland
isla.sutherland@terrapinn.com
Marketing Opportunities
Hidy Lee
hidy.lee@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events